+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Janus Kinase (JAK) Inhibitors Market 2019-2023 - Product Image

Global Janus Kinase (JAK) Inhibitors Market 2019-2023

  • ID: 4808272
  • Report
  • July 2019
  • Region: Global
  • 133 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • Eli Lilly and Co.
  • Incyte Corp.
  • Novartis AG
  • Pfizer Inc.
  • MORE
Global Janus Kinase (JAK) Inhibitors Market: About this market

Global janus kinase (JAK) inhibitors are drugs that inhibit the abnormal functionality of enzymes in the JAK family such as JAK1, JAK2, JAK3, and TYK2. The inhibition of these enzymes helps interfere with the JAK-STAT signaling pathway, which has been found to play a key role in the development of various autoimmune disorders and cancer indications. The janus kinase (JAK) inhibitors market analysis considers sales from both autoimmune disorder and oncology. Our analysis also considers the sales of janus kinase (JAK) inhibitors in Asia, Europe, North America, ROW.

In 2018, the autoimmune disorders segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as high proven efficiency of these drugs will play a significant role in the autoimmune disorders segment to maintain its market position. Also, our global janus kinase (JAK) inhibitors market report also looks at factors such as increasing number of awareness campaigns, application in severe chronic indications, support from the growing healthcare insurance industry. However, the availability of alternative therapies, differential drug pricing, strong adverse effects may hamper the growth of the janus kinase (JAK) inhibitors industry over the forecast period.

Global Janus Kinase (JAK) Inhibitors Market: Overview

Application in severe chronic indications

The global JAK inhibitors market is expected to benefit significantly from the rising use of JAK inhibitors to treat various chronic diseases. The high efficacy of JAK inhibitors for the treatment of autoimmune disorders has increased their adoption for the treatment of rheumatoid arthritis, psoriatic arthritis. and ulcerative colitis. Research on the use of JAK inhibitors has shown significant results in the clinical stages, which has created the market potential for the vendors. Similarly, the unmet need for the treatment of graft-versus-host disease (GVHD) is high as the treatment landscape is dominated by off-label of therapies such as TNF inhibitors and interleukin inhibitors. To address the high unmet need, vendors in the global JAK inhibitors market are developing novel drugs to treat GVHD. Such factors will lead to the expansion of the global janus kinase (JAK) inhibitors market at a CAGR of over 18% during the forecast period.

Special drug designations

One of the major benefits that most JAK inhibitors have is the special drug designations given by regulatory bodies. Many drugs have received designations such as the orphan drug designation from regulatory bodies such as the US FDA and the EMA. The orphan drug designation is given to a drug by the FDA when it is being developed to treat an indication that less than 200.000 people have in the US. Vendors that have received the orphan drug designation for their drug will get certain benefits associated with regulations and taxes. This development is expected to have a positive impact on the overall market growth.

Competitive Landscape

With the presence of a few major players, the global janus kinase (JAK) inhibitors market is concentrated. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading janus kinase (JAK) inhibitors manufacturers, that include Astellas Pharma Inc., Eli Lilly and Co., Incyte Corp., Novartis AG, and Pfizer Inc.

Also, the janus kinase (JAK) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • Eli Lilly and Co.
  • Incyte Corp.
  • Novartis AG
  • Pfizer Inc.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY APPLICATION
  • Market segmentation by application
  • Comparison by application
  • Autoimmune disorders - Market size and forecast 2018-2023
  • Oncology - Market size and forecast 2018-2023
  • Market opportunity by application
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • Increasing research grants
  • Special drug designations
  • Rising number of strategic alliances
PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Astellas Pharma Inc.
  • Eli Lilly and Co.
  • Incyte Corp.
  • Novartis AG
  • Pfizer Inc.
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits:
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Application - Market share 2018-2023 (%)
Exhibit 19: Comparison by application
Exhibit 20: Autoimmune disorders - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Pipeline of JAK inhibitors for autoimmune disorders
Exhibit 22: Autoimmune disorders - Year-over-year growth 2019-2023 (%)
Exhibit 23: Oncology - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Pipeline of JAK inhibitors for oncology
Exhibit 25: Oncology - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by application
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in North America
Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Europe
Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in Asia
Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 40: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in ROW
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: Astellas Pharma Inc. - Vendor overview
Exhibit 51: Astellas Pharma Inc. - Business segments
Exhibit 52: Astellas Pharma Inc. - Organizational developments
Exhibit 53: Astellas Pharma Inc. - Geographic focus
Exhibit 54: Astellas Pharma Inc. - Key offerings
Exhibit 55: Astellas Pharma Inc. - Key customers
Exhibit 56: Eli Lilly and Co. - Vendor overview
Exhibit 57: Eli Lilly and Co. - Business segments
Exhibit 58: Eli Lilly and Co. - Organizational developments
Exhibit 59: Eli Lilly and Co. - Geographic focus
Exhibit 60: Eli Lilly and Co. - Segment focus
Exhibit 61: Eli Lilly and Co. - Key offerings
Exhibit 62: Eli Lilly and Co. - Key customers
Exhibit 63: Incyte Corp. - Vendor overview
Exhibit 64: Incyte Corp. - Business segments
Exhibit 65: Incyte Corp. - Organizational developments
Exhibit 66: Incyte Corp. - Geographic focus
Exhibit 67: Incyte Corp. - Key offerings
Exhibit 68: Incyte Corp. - Key customers
Exhibit 69: Novartis AG - Vendor overview
Exhibit 70: Novartis AG - Business segments
Exhibit 71: Novartis AG - Organizational developments
Exhibit 72: Novartis AG - Geographic focus
Exhibit 73: Novartis AG - Segment focus
Exhibit 74: Novartis AG - Key offerings
Exhibit 75: Novartis AG - Key customers
Exhibit 76: Pfizer Inc. - Vendor overview
Exhibit 77: Pfizer Inc. - Business segments
Exhibit 78: Pfizer Inc. - Organizational developments
Exhibit 79: Pfizer Inc. - Geographic focus
Exhibit 80: Pfizer Inc. - Segment focus
Exhibit 81: Pfizer Inc. - Key offerings
Exhibit 82: Pfizer Inc. - Key customers
Exhibit 83: Validation techniques employed for market sizing
Exhibit 84: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • Eli Lilly and Co.
  • Incyte Corp.
  • Novartis AG
  • Pfizer Inc.
  • MORE
The following companies are recognised as the key players in the global janus kinase (JAK) inhibitors market: Astellas Pharma Inc., Eli Lilly and Co., Incyte Corp., Novartis AG, and Pfizer Inc.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the special drug designations.”

According to the report, one of the major drivers for this market is the application in severe chronic indications.

Further, the report states that one of the major factors hindering the growth of this market is the differential drug pricing.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Astellas Pharma Inc.
  • Eli Lilly and Co.
  • Incyte Corp.
  • Novartis AG
  • Pfizer Inc.
Note: Product cover images may vary from those shown
Adroll
adroll